A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Conditions
Non-Small Cell Lung Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of California Irvine, Orange, California, United States
Orchard Healthcare Research Inc., Skokie, Illinois, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Detroit Clinical Research Center, Farmington Hills, Michigan, United States
Morristown Medical Center, Morristown, New Jersey, United States
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Oncology Hematology Care Clinical Trials LLC, Cincinnati, Ohio, United States
Providence Portland Medical Center, Portland, Oregon, United States
University Of Nebraska Medical Center, Portland, Oregon, United States
Lifespan Cancer Institute, Providence, Rhode Island, United States
Prairie Lakes Healthcare System, Watertown, South Dakota, United States
University of Tennessee Medical Center, Knoxville, Tennessee, United States
Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville, Tennessee, United States
Tennessee Oncology, Nashville, Tennessee, United States
BRCC/Oncology & Hematology Associates of SW Virginia, Blacksburg, Virginia, United States
Oncology Clinical Research Center, Cachoeiro de Itapemirim, Espírito Santo, Brazil
Instituto Mario Penna, Belo Horizonte, Minas Gerais, Brazil
Instituto Sul Mineiro De Oncologia LTDA, Pouso Alegre, Minas Gerais, Brazil
Instituto de Medicina Integral Professor Fernando Figueira, Recife, Pernambuco, Brazil
Liga Norte Riograndense Contra o Cancer, Natal, Rio Grande do Norte, Brazil
Hospital Mae de Deus Integrated Oncology Center, Porto Alegre, Rio Grande do Sul, Brazil
Hospital Sao Lucas da PUCRS, Porto Alegre, Rio Grande do Sul, Brazil
Ynova Pesquisa Clinica, Florianópolis, Santa Catarina, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto, São José do Rio Preto, São Paulo, Brazil
Unimed Sorocaba, Sorocaba, São Paulo, Brazil
Hospital Alemao Oswaldo Cruz, São Paulo, Brazil
CHU Rennes, Rennes, Brittany Region, France
Centre Hospitalier Intercommunal Toulon - CHITS, Toulon, Var, France
Centre Hospitalier de la Cote Basque, Bayonne, France
Clinique Belharra, Bayonne, France
CHU Grenoble Alpes, Grenoble, France
Montpellier Academic Hospital, Montpellier, France
Institut Curie, Paris, Île-de-France Region, France
Klinikum Kassel GmbH, Hauttumorzentrum, Kassel, Hesse, Germany
University Medicine Gottingen, Göttingen, Lower Saxony, Germany
University of Leipzig, Leipzig, Saxony, Germany
University Hospital RWTH Aachen, Aachen, Germany
Catalan Instituye of Oncology Badalona, Badalona, Barcelona, Spain
Hospital Valdecilla, Santander, Cantabria, Spain
Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Las Palmas, Spain
Clinica Universidad de Navarra, Pamplona, Navarre, Spain
MD Anderson Cancer Center, Madrid, Spain
Hospital Universitario Clinico San Carlos, Madrid, Spain
Hospital Universitario La Paz, Madrid, Spain
Hospital Universitario HM Sanchinarro, Madrid, Spain
Hospital Virgen del Rocio, Seville, Spain
Hospital Clinico Universitario Valencia, Valencia, Spain
Consorci Hospital General Universitario de Valencia, Valencia, Spain
Hospital Clinico Lozano Blesa, Zaragoza, Spain
Florya Medical Park Hospital, Istanbul, Turkey (Türkiye)
Study leads
Clinical Trial Management
Study Director
Regeneron Pharmaceuticals